Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib +/- LDAC in AML
NCT00804856Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2008
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of volasertib in acute myeloid leukemia (AML), sponsored by Boehringer Ingelheim. Started Nov 2008; status: completed.
02
Drugs
volasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00804856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00804856.